Fresenius SE & Co. KGaA/ DE0005785604 /

12/8/2023 8:28:59 PM	Chg. -	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
30.6742USD	-	2,745 Turnover: 84,200.6790	-Bid Size: -	-Ask Size: -	17.07 bill.USD	-	-

GlobeNewswire 6/11/2021 UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

GlobeNewswire 6/11/2021 Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

GlobeNewswire 11/11/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 11/7/2019 eGenesis Announces $100 Million Series B Financing

GlobeNewswire 11/4/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/29/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...

GlobeNewswire 10/23/2019 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...

TeleTrader 8/7/2017 Fresenius Medical buys NxStage for $2 billion

GlobeNewswire 7/19/2017 Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi

GlobeNewswire 6/9/2017 KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

GlobeNewswire 4/7/2017 Akorn Confirms Discussions with Fresenius Kabi

GlobeNewswire 1/27/2011 Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®